The MagnetisMM studies are committed to finding potential treatment options

You don’t have to take on multiple myeloma alone

We know it takes a full support system to take on multiple myeloma.
And we’re here to explore a potential way to fight it with you.

The MagnetisMM clinical research studies will evaluate the safety and effectiveness of a study medicine, elranatamab, in people with multiple myeloma. Participating in a study is an important and personal decision. We want you to know that we will be with you every step of the way.

Participating in these studies

Each MagnetisMM study will have its own unique requirements for who may participate (eligibility criteria). 


The requirements may include your stage of multiple myeloma as well as any previous treatments you may have received. 


You can talk with the study doctor to find out which study may be right for you.


Multiple myeloma


The disease, disorder, syndrome, illness, or injury that is being studied.


18+ years


The age a person must be to participate in at least one of the studies in this programme.


Male or Female


The sex of people who may participate in at least one of the studies in this programme. Sex is a person’s classification based on assignment at birth. Eligibility based on sex is distinct from eligibility based on gender.

This information is a summary of the eligibility criteria across the studies in this programme. Each study will have its own unique requirements for who may participate (eligibility criteria). To learn more about the requirements for a study that is actively recruiting, visit the study’s webpage below. 
Only the research study staff can determine if you qualify to enrol in the study.

Recruitment paused

MagnetisMM clinical research studies


MagnetisMM-7—for participants with newly diagnosed multiple myeloma who are minimal residual disease (MRD)-positive following autologous stem cell transplantation (ASCT)

A phase 3 study of the study medicine, elranatamab versus a comparator medicine, lenalidomide, in patients with newly diagnosed multiple myeloma who are MRD-positive after undergoing ASCT.


MagnetisMM-6—for people who have tried 1-2 prior treatments or are newly-diagnosed and not eligible for transplant

A phase 3 study assessing the investigational study medicine, elranatamab, compared to standard therapy (a combination of daratumumab + lenalidomide+ dexamethasone).

About multiple myeloma

Multiple myeloma is a type of blood cancer that forms in your bone marrow. Multiple myeloma starts when healthy plasma cells change and grow at a rapid pace.

  • Abnormal (myeloma or cancer) plasma cells overcrowd and/or prevent the creation and growth of healthy plasma cells and other cells within the bone marrow
  • Like healthy plasma cells, myeloma cells create antibodies; however, the antibodies don’t work properly, lowering your body’s ability to fight infection
  • Abnormal plasma cells also build up in your bones and organs, making it difficult for them to work properly

About the study medicine

The MagnetisMM studies will evaluate the safety and effectiveness of the study medicine, elranatamab, which will be given as a subcutaneous (SC) injection. An SC injection is a needle inserted under the skin in order to deliver the study medicine.


The study medicine elranatamab is thought to work by connecting certain immune system cells, known as T-cells, to myeloma cells. Connecting these cells activates the immune cells to kill the myeloma cells.

The importance of representation

Diversity among study participants is important in order to understand whether potential treatments work in different people. Race, ethnicity, age, and sex can all impact how different people respond to the same treatment.

When groups of people aren’t well represented in research, we cannot know if the study medicine may work properly for all the people it is trying to help. 

When you take part in a study, you’re helping to represent both your community and all people who are affected by multiple myeloma.